Project Grant R01HL178625
Award Date
8/1/25
Completion Date
4/30/30
Dollars Obligated
$657K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996 to the University of Southern California (USC) from April 1, 2025 to January 31, 2029. The funding supports research to investigate the role of the protein PDLIM2 in regulating alveolar macrophage function, which is critical for lung innate immunity, inflammation, and respiratory diseases. The research aims to elucidate the...
This Project Grant award of $759,983 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the University of North Carolina at Chapel Hill supports research examining the diverse responses of neutrophils during Streptococcus pneumoniae pneumonia and acute lung injury. The research aims to determine changes in neutrophil transcriptomes and the lung microenvironment during the development and resolution of S. pneumoniae-induced inflammation and...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
This federal Project Grant award, totaling $756,875.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati. The award supports research to investigate the fundamental mechanisms by which neutrophil extracellular traps (NETs) contribute to airway damage and infection in mucoobstructive lung diseases, such as cystic fibrosis. Key research aims include examining how NET-mediated...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $579,309 to the University of Toledo's Health Science Campus Division to conduct research on the role of cysteinyl leukotriene receptor signaling in regulating macrophage function and lung inflammation. The research aims to elucidate the mechanistic aspects of how the CYSLT1R receptor promotes an inflammatory macrophage phenotype,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,831,848 to the University of Rochester to investigate how neonatal microbiome colonization impacts lung immunity and regeneration. The research aims to elucidate how early-life microbial dysbiosis remodels the developmental program in lung-resident lymphocytes and epithelial cells, contributing to chronic respiratory disease. Key...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on extending neutrophil survival to treat and prevent neutropenia-related bacterial pneumonia. The $676,748 award to Brigham & Women's Hospital Inc. aims to investigate the role of Gasdermin D (GSDMD) in regulating neutrophil lifespan and evaluate GSDMD inhibition as a potential therapeutic strategy. The research will uncover the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $148,568.00 to Mayo Clinic to investigate the role of pleural mesothelial cells in lung injury, repair, and regeneration. The project will utilize lineage-tracing experiments in mouse models to study the function of these cells in the context of lung fibrosis and regeneration. The research aims to elucidate the signaling...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...